Health Care Blog November 5, 2025
Artificial intelligence (“AI”) has taken root in the field of drug discovery and development and already has shown signs of running past the traditional model of doing research. Congress should take note of these rapid changes and: 1) direct the Department of Health and Human Services (“HHS”) to phase down the government’s basic research grant program for non-Ai applicants, 2) require HHS to redirect these monies to fund nascent artificial intelligence applications, and 3) require HHS to revamp the roadmap for drug approvals of AI-driven trials to reflect the new capabilities for drug discovery and development.
Background
There are four distinguishing features of the U.S. healthcare industry.
First, the industry’s costs as a percentage of GNP have increased from 8%...
Today's Sponsors
Today's Sponsor